Sep 18, 2006 by Brian LawlerCell Therapeutics' New MateThe biopharmaceutical company removes some uncertainty by teaming up with Novartis.
Sep 15, 2006 by Brian LawlerGlaxo's Burgeoning BlockbusterA drug to lower blood sugar could also help prevent type 2 diabetes.
Sep 14, 2006 by Brian LawlerGood Buy for Biogen IdecIts past success bodes well for its plans for a new blood pressure drug.
Sep 13, 2006 by Brian LawlerWhat to Make of Bristol-MyersTake a good look at the industry to try to sort out the meaning of all the news and the rumors.
Sep 12, 2006 by Brian LawlerThose Buybacks at QLTIs the company repurchasing shares to make itself more attractive for an acquisition?
Sep 12, 2006 by Brian LawlerGlaxo's Big Tax BillNo tax evasion schemes here, just differing guesstimates.
Sep 11, 2006 by Brian LawlerMore Work on Cancer Drug for GenentechThe FDA asks for more data about Avastin, which could be used to treat various cancers.
Sep 8, 2006 by Brian LawlerLigand's Drug SaleFor the pharmaceutical's marketed drugs, everything must go.
Sep 7, 2006 by Brian LawlerSkyePharma Makes a DealThe pharmaceutical sells European rights to a promising asthma drug.
Sep 7, 2006 by Brian LawlerWhere's the Love for Martek?Disappointing guidance marks this winner as a loser.
Sep 6, 2006 by Brian LawlerAnorMED's Tumultuous YearA takeover attempt follows management shakeups at the biopharmaceutical firm.
Sep 6, 2006 by Brian LawlerCatalyst for ZymoGenetics?Trial results for a drug that controls bleeding include a favorable comparison with a similar product.
Sep 5, 2006 by Brian LawlerNeurocrine Wakes Up IndiplonThe biotech company announces new drug delays.
Sep 5, 2006 by Brian LawlerAdolor: Positive Results, Negative ReactionThe market seems confused by good results from Adolor's latest clinical trial.
Sep 1, 2006 by Brian LawlerBristol-Myers and Sanofi Get Apotex to StopA temporary injunction against Apotex means big news for all the companies involved.
Aug 29, 2006 by Brian LawlerMore Good News for RituxanGenentech and Biogen Idec's drug shows positive results against multiple sclerosis.
Aug 28, 2006 by Brian LawlerThe Commandments of Biotech InvestingInvest carefully in biotech to avoid some common pitfalls.
Aug 22, 2006 by Brian LawlerSticking With Myriad GeneticsThe potential for growth in one division offsets the risk in its trials for an Alzheimer's drug.
